The CALMA trial reached approximately 70% enrollment as of February 2026, with completion expected by mid-2026 before database lock and topline results. The pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The company is positioning itself at the intersection of AI-driven drug discovery and cannabinoid therapeutics for CNS disorders.
Cyborg Score Rationale
IGC Pharma shows focused clinical execution with a Phase 2 trial approaching completion, but faces typical biotech risks: capital constraints (multiple small funding rounds in 2025-2026), micro-cap trading status, and unproven commercial viability. Near-term catalyst (CALMA topline data expected mid-2026) could materially impact valuation.
Top Insights
CALMA trial enrollment reached ~70% in February 2026 with topline results expected by mid-2026, providing near-term value catalyst
Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting, differentiating from traditional cannabinoid-focused peers
Expanded Phase 2 trial to Colombia (February 2026) with 23 active sites across US, Canada, and Colombia to broaden genetic diversity
Launched strategic media partnership with New to The Street (March 2026) to expand investor awareness across institutional and retail audiences
Named Competitors
Aducanumab — Monoclonal antibody targeting amyloid-beta in Alzheimer's disease
Lecanemab (Leqembi) — Anti-amyloid monoclonal antibody for early Alzheimer's disease
Donanemab (Kisunla) — Anti-amyloid monoclonal antibody for mild cognitive impairment and mild dementia